Delivering timely service and evidence-informed resources to people in BC and the Yukon facing cancer and those involved in oncology care or research.
The original 1999 report was published as "Review of the potential health risks of radiofrequency fields from wireless telecommunications devices" / Expert Panel on the Potential Health Risks of Radiofrequency Fields from Wireless Telecommunications Devices - Ottawa, ON: Royal Society of Ca…
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency KEL Library | Available | ||
c.1 BC Cancer Agency SUR Library | Available |
The original 1999 report was published as "Review of the potential health risks of radiofrequency fields from wireless telecommunications devices" / Expert Panel on the Potential Health Risks of Radiofrequency Fields from Wireless Telecommunications Devices - Ottawa, ON: Royal Society of Ca…
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency KEL Library | Available | ||
c.1 BC Cancer Agency SUR Library | Available | ||
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency VIC Library | Available |
The original 1999 report was published as "Review of the potential health risks of radiofrequency fields from wireless telecommunications devices" / Expert Panel on the Potential Health Risks of Radiofrequency Fields from Wireless Telecommunications Devices - Ottawa, ON: Royal Society of Ca…
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available |
c.1 BC Cancer Agency KEL Library | Available | ||
c.1 BC Cancer Agency SUR Library | Available | ||
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
The majority of the articles from the May 2013 CHEST Supplement "Lung cancer guidelines" are online only. The individual chapters are only available as electronic files. The print edition only includes the following articles which are free online to view: Disclaimer; Panel List; Executive Summary…
Table of Contents:; 1. Immunotherapy administration; 2. Immunotherapy; 3. Cancer immunotherapy; 4. CAR T-cell therapy; 5. Cytokine release syndrome; 6. Developming infrastructure; 7. Immunotherapy toxicities; 8. Checkpoint inhibitors; 9. Toxicity managment; 10.Oncolytic viruses
c.1 BC Cancer Agency VAN Library | Available | ||
c.2 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency KEL Library | Available |
This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 2-9 February 2016